Danaher Corporation (DHR)
NYSE: DHR · Real-Time Price · USD
190.05
-5.11 (-2.62%)
At close: Sep 12, 2025, 4:00 PM EDT
191.85
+1.80 (0.95%)
After-hours: Sep 12, 2025, 7:47 PM EDT
Danaher Revenue
Danaher had revenue of $5.94B in the quarter ending June 27, 2025, with 3.36% growth. This brings the company's revenue in the last twelve months to $24.01B, up 1.89% year-over-year. In the year 2024, Danaher had annual revenue of $23.88B, down -0.06%.
Revenue (ttm)
$24.01B
Revenue Growth
+1.89%
P/S Ratio
5.70
Revenue / Employee
$381,159
Employees
63,000
Market Cap
136.09B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 23.88B | -15.00M | -0.06% |
| Dec 31, 2023 | 23.89B | -2.75B | -10.33% |
| Dec 31, 2022 | 26.64B | 1.84B | 7.42% |
| Dec 31, 2021 | 24.80B | 2.52B | 11.30% |
| Dec 31, 2020 | 22.28B | 4.37B | 24.42% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
DHR News
- 2 days ago - Rosen Law Firm Investigates Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation – DHR - GlobeNewsWire
- 3 days ago - Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation - DHR - PRNewsWire
- 3 days ago - Beckman Coulter Diagnostics Launches Industry First Fully Automated, High Throughput BD-Tau Research Use Only Immunoassay Test, Advancing Neurodegenerative Clinical Research - PRNewsWire
- 4 days ago - Danaher Announces Quarterly Dividend - PRNewsWire
- 8 days ago - DHR Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation - DHR - PRNewsWire
- 17 days ago - mRNA Biotechs - Long-Term Value Risks Abound - Seeking Alpha
- 5 weeks ago - Analysts' Top S&P 500 Stocks to Buy Now - Kiplinger
- 5 weeks ago - Danaher Stock Closes Near Day's High After Key Trading Signal - Benzinga